Affiliations 

  • 1 Infection Biology, Department of Life Sciences, Central University of Tamil Nadu, Neelakudi, Thiruvarur 610005, India
  • 2 Unit for Lung and Airway Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
  • 3 Laboratory Centre, Xiamen University, Sepang, Malaysia
  • 4 Department of Microbiology, Saveetha Dental College and Hospital, Chennai, India
  • 5 Division of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA USA
  • 6 Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates
  • 7 Molecular Medicine and Virology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
Pathog Dis, 2021 Jan 09;79(1).
PMID: 33289808 DOI: 10.1093/femspd/ftaa076

Abstract

A vast proportion of coronavirus disease 2019 (COVID-19) individuals remain asymptomatic and can shed severe acute respiratory syndrome (SARS-CoV) type 2 virus to transmit the infection, which also explains the exponential increase in the number of COVID-19 cases globally. Furthermore, the rate of recovery from clinical COVID-19 in certain pockets of the globe is surprisingly high. Based on published reports and available literature, here, we speculated a few immunovirological mechanisms as to why a vast majority of individuals remain asymptomatic similar to exotic animal (bats and pangolins) reservoirs that remain refractile to disease development despite carrying a huge load of diverse insidious viral species, and whether such evolutionary advantage would unveil therapeutic strategies against COVID-19 infection in humans. Understanding the unique mechanisms that exotic animal species employ to achieve viral control, as well as inflammatory regulation, appears to hold key clues to the development of therapeutic versatility against COVID-19.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.